EDAP TMS S.A. (EDAP), incorporated on April 20, 1983, is a holding company engaged in developing and marketing the Ablatherm and Focal One devices. The Company operates two divisions: High Intensity Focused Ultrasound (HIFU) and Urology Devices and Services (UDS) (including lithotripsy activities). It offers products for HIFU treatment of localized prostate cancer. Through these two divisions, the Company develops, produces and markets medical devices, mainly for urological diseases. The Company's HIFU and UDS divisions operate in Europe, the Americas, Asia and the rest of the world. The Company is developing HIFU technology for the treatment of certain other types of tumors. The Company also produces and commercializes medical equipment for treatment of urinary tract stones using extra-corporeal shockwave lithotripsy (ESWL) and distributes other types of urology devices in certain countries.
High Intensity Focused Ultrasound Division
The Company's HIFU division is engaged in the development, manufacturing and marketing of medical devices based on HIFU technology for the invasive treatment of urological and other clinical indications. HIFU technology uses a high-intensity convergent ultrasound beam generated by high power transducers to produce heat. HIFU technology is intended to allow the surgeon to destroy a well-defined area of diseased tissue without damaging surrounding tissue and organs, thereby eliminating the need for incisions, transfusions and general anesthesia and associated complications. The Company's HIFU Division markets two HIFU devices: the Ablatherm and the Focal One. The Ablatherm is used for the treatment of organ-confined prostate cancer, referred to as T1-T2 stage. Ablatherm is approved for commercial distribution in the European Union, the United States, South Korea, Canada, Australia, Taiwan, South Africa, New Zealand, the Philippines, Argentina, Mexico, Brazil, Russia, Venezuela, Peru and Ecuador. HIFU Division also produces and markets the Focal One device, a HIFU robotic device for the focal therapy of localized prostate cancer, thereby destroying focused cancer cells only. Focal One is approved for commercial distribution in the European Union, Canada, Saudi Arabia, South Korea, Peru and Chile. The Company's HIFU division has an installed base of approximately 100 Ablatherm machines, over 14 Focal One and approximately 350 trained clinical sites across the world were using this technology. In addition, the HIFU division is also engaged in leasing equipment, as well as the sale of disposables, spare parts and maintenance services. The Company's HIFU mobile treatment option provides access to the HIFU devices without requiring hospitals and clinics to make an up-front investment in the equipment. Instead, hospitals and clinics perform treatments using these devices.
The Company competes with SonaCare Medical, General Electric, Theraclion, Elbit Medical Imaging, Haifu and Philips Healthcare.
Urology Devices and Services Division
The Company's UDS division is engaged in the development, marketing, manufacturing and servicing of medical devices for the minimally invasive diagnosis or treatment of urological disorders, urinary stones, and other clinical indications. The Company's UDS division's primary business is producing and marketing devices, known as lithotripters, for the treatment of urinary tract stones by means of ESWL technology. The UDS division manufactures two models of lithotripters: the Sonolith i-move and the Sonolith i-sys. The UDS division sells over 827 ESWL lithotripters across the world and maintains otherwise serviced 608 installed lithotripters. The Company is also engaged in the leasing of lithotripters, as well as the sale of disposables, spare parts and maintenance services. The Company manufactures its own products as part of EDAP TMS France SAS, its subsidiary. The Company offers the Sonolith i-move to small and mid-size hospitals, while the Sonolith i-sys is offered to large hospitals. The UDS division also sells disposable parts for lithotripters, including the piezoelectric elements of the LT02 and the electrodes of the Sonolith line. The Sonolith i-move is available for commercial distribution in the European Union, South Korea, Malaysia, Peru, Venezuela, Colombia, Costa Rica, Japan, the United States, Taiwan, Singapore, Saudi Arabia, Mexico and Brazil. The Sonolith i-sys is available in the European Union, South Korea, Canada, the United States, Peru, Colombia, Argentina, Venezuela, Mexico, Costa Rica, Japan, Australia, Malaysia, Singapore, Saudi Arabia and Taiwan. The Company distributes urodynamic products on behalf of Medical Measurement Systems (MMS) and Andromeda in Japan, and laser urology solutions from Lumenis in France.
The Company competes with Siemens, Storz and Dornier.
Parc Activite
The company trades on NASDAQ exchange. The company headquarter is located in France. The company was established in the 1979.| Ticker | EDAP |
| Long Name | EDAP TMS S.A. |
| Short Name | EDAP TMS |